New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|May 15, 2002
- BioPharm International-05-01-2002
- Volume 15
- Issue 5
Development of an In Situ Spectroscopic Method for Cleaning Validation using Mid-IR Fiber-Optics
by Narinder K. Mehta, Javier Goenaga-Polo, Samuel P. Hernandez-Rivera, David Hernandez, Peter J. Melling, and Mary A. Thomson, Remspec Corporation A fiber-optic, mid-IR spectroscopy probe combined with a grazing-angle reflectance sampling head can be used as a solvent-free in situ method for validating cleanliness with substantial improvement in accuracy.
Advertisement
Articles in this issue
over 24 years ago
Info+over 24 years ago
Analytical Advances: Strategies in Clarifying Mammalian Culturesover 24 years ago
Analytical Advances: Using Image Informatics - Focusing Proteomicsover 24 years ago
The Not-So-Sure Thingover 24 years ago
Washington Report: Vaccine Shortages put Spotlight on Productionover 24 years ago
Guest Editorial: Validation Bingoover 24 years ago
Travel Notes: Yes, Virginia, There is Biotech in the CommonwealthAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement